Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

This study tests whether giving a higher radiation dose to a brain area called the subventricular zone (where stem cells live) can delay glioblastoma from coming back. About 60 adults with newly diagnosed glioblastoma will receive standard radiation and chemo, but half will get e…

This early-phase trial tests whether giving the immunotherapy drugs nivolumab (Opdivo) with or without relatlimab before and after surgery is safe and feasible for people with liver cancer that can be removed. About 31 participants will receive the drugs before surgery, then cont…

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) before surgery is safe and feasible for people with resectable malignant pleural mesothelioma. About 30 adults with epithelial or biphasic mesothelioma will receive the drugs, then undergo …

This phase 2 trial tests whether continuing the drug palbociclib (Ibrance) while switching to a different hormone therapy, fulvestrant (Faslodex), can help control metastatic breast cancer in people whose disease has worsened on palbociclib plus an aromatase inhibitor. The study …

This study tests different combinations of immunotherapy drugs given before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if these treatments can help the immune system fight the cancer better and improve outcomes. About 76 participan…

This phase 2 trial tests a low-dose combination of five chemotherapy drugs (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan) followed by two maintenance drugs (olaparib and pembrolizumab) in 38 people with untreated metastatic pancreatic cancer. The goal is to se…

This study tests a drug called blinatumomab given after a stem cell transplant to help prevent relapse in people with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. About 44 participants will receive the drug as maintenance therapy. The goal is to see if it i…

This study tests whether giving two drugs—nivolumab and an anti-IL-8 antibody—before surgery is safe and feasible for people with head and neck cancer. About 24 participants will receive the combination before their operation. The goal is to see if this approach can help shrink t…

This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process that cancer cells rely on, especially those with certain DNA faults. The main goal is to see if the drug can…

This early-stage trial tests whether combining a precise form of radiation (stereotactic radiosurgery) with two immunotherapy drugs (MBG453 and spartalizumab) is safe for people whose glioblastoma has come back. The study includes 16 adults with recurrent GBM. The main goal is to…

This study tests two immunotherapy drugs (nivolumab with or without urelumab) given before bladder removal surgery in 15 patients with muscle-invasive bladder cancer who cannot or refuse standard chemotherapy. The goal is to see if adding urelumab boosts the immune response again…

This early-phase trial tests whether immune cells from a vaccinated relative can help treat advanced HPV16-related cancers. Up to 24 patients will receive either a bone marrow transplant or a special infusion of donor immune cells. The main goals are to check safety and find the …

This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemorad…

This study tests whether combining hormone therapy, a targeted drug (palbociclib), and an immunotherapy (avelumab) can shrink early-stage, hormone-positive breast tumors before surgery. About 33 women with stage II-III breast cancer will receive the treatment for about 4 months, …

This phase 2 trial tests whether combining two immunotherapy drugs, nivolumab and relatlimab, can shrink or control advanced solid tumors with a specific genetic feature (MSI-H) that have stopped responding to prior immunotherapy. About 38 adults with these hard-to-treat cancers …

This early-phase trial tests an HPV vaccine series in healthy relatives of patients with advanced HPV-related cancer. The goal is to generate HPV-specific white blood cells that can be collected and used in a bone marrow transplant or donor lymphocyte infusion for the patient. Th…

This study looked at whether adding a drug called vorinostat to standard chemotherapy (carboplatin and nab-paclitaxel) before surgery helps shrink tumors more in women with HER2-negative breast cancer. About 68 women took part. The goal was to see if the combination leads to no c…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This early-phase study tests the safety of combining an immunotherapy drug (nivolumab) with or without precise radiation (stereotactic radiosurgery) in 21 people with chordoma that has returned or spread. The goal is to see if this combination causes fewer side effects and helps …

This study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…

This phase 2 study is testing a combination of three drugs—paclitaxel (a chemotherapy), pembrolizumab (an immunotherapy), and olaparib (a targeted therapy)—in 36 adults with advanced gastric or gastroesophageal cancer that has worsened after one prior treatment. The goal is to se…

This early-phase trial is testing a vaccine that targets mutated KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with pancreatic or colorectal cancer that has been surgically removed. The goal is to see if the vaccine can safely boo…

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were…

This study tested a combination of two chemotherapy drugs, gemcitabine and docetaxel, placed directly into the bladder for people with early-stage bladder cancer who had not received standard BCG therapy. The goal was to see if this treatment could prevent the cancer from coming …

This early-phase trial tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) after a mini stem cell transplant in people aged 60 and older with certain blood cancers. The study also aims to see if itacitinib allows doctors to use…

This study planned to test a targeted cancer pill (adagrasib) alone or with an immunotherapy drug (nivolumab) before surgery in people with a specific type of lung cancer (KRAS G12C mutation). The goal was to see if these drugs could eliminate all cancer cells by the time of surg…

This study tests whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 ng/mL and no prior biopsy will receive the scan before their standard biop…

This study tests a modified whole brain radiation technique that avoids a specific area of the brain called the corpus callosum genu, which is important for memory and thinking. The goal is to see if this approach helps preserve cognitive function in people with brain metastases …

This early-phase study tests a new type of proton therapy called Pro-GRID for people with large tumors (over 7 cm) that are hard to treat. The goal is to see if the treatment is safe and can shrink tumors or ease symptoms. About 11 adults with sarcoma or melanoma are taking part.

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study at Johns Hopkins is testing whether genetic information from a blood sample can match what is found in a tumor biopsy for people with metastatic breast cancer. Researchers will use the results to suggest personalized treatment options. The goal is to see if a simple bl…

This study creates a long-term repository of blood, tissue, and health information from 810 people with breast cancer, benign breast disease, or no breast issues. The goal is to provide researchers with resources to better understand breast cancer. No treatment or experimental th…

This early-phase study tests whether adding targeted radiation to immunotherapy drugs (nivolumab with or without relatlimab) is safe and can boost the immune system's attack on advanced stomach or esophageal cancer. About 21 adults with limited metastatic disease will receive rad…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to build a biobank for research into how the cancer responds to radiation. No participants were enrolled, and the study was withdrawn before it began.

This study explores whether advanced MRI scans can detect early changes in prostate tumors and nearby healthy tissues during radiation therapy. By spotting these changes sooner, doctors might adjust treatment to improve effectiveness and reduce side effects. The study involves 38…